Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In Vivo and in Vitro Assessment of Residual DNA Impurity-Derived Transcriptions [II]

ABSTRACT: In Vivo and in Vitro Assessment of Residual DNA Impurity-Derived Transcriptions [II]

PROVIDER: PRJNA1180539 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31181823_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 1 of 1

Similar Datasets

In Vivo and in Vitro Assessment of Residual DNA Impurity-Derived Transcriptions [I]

Project description:In Vivo and in Vitro Assessment of Residual DNA Impurity-Derived Transcriptions [I]

| PRJNA1180538 | ENA

In Vivo and in Vitro Assessment of Residual DNA Impurity-Derived Transcriptions [II]

Project description:Gene therapy products, such as rAAV, are typically produced by DNA plasmid transfected to mammalian cell lines. Host cell DNA and plasmid DNA can be inadvertently packaged inside the rAAV capsids during production. It is important to characterize these residual DNA impurities in gene therapy products due to the theoretical risk of immunogenicity, infectivity, and oncogenicity. Previous studies showed the level of residual DNA impurity is around 1-2% of the expected rAAV genome. However, it remains unclear whether these DNAs undergo transcription and translation. To address this question, RNA was isolated from mouse liver various days after rAAV transduction, followed by reverse transcription for cDNA synthesis and library preparation. RNA-seq and dPCR were used to quantify the level of the gene of interest and the impurity genes. Results showed a low but detectable level of AAVhu37 Cap, AAV2 Rep, and KanR transcripts. The result from these studies enables targeted risk assessment and better understanding of the potential adverse effects associated with AAV gene therapy. It also points to the importance of improving vector design to reduce the level of DNA impurities.

2025-05-09 | GSE280789 | GEO

In Vivo and in Vitro Assessment of Residual DNA Impurity-Derived Transcriptions [I]

2025-05-09 | GSE280788 | GEO

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

| PRJNA1014444 | ENA

In vivo isolated Wnt1-Prim1 Primary, Residual, and Recurrent Tumor Cells

Project description:Residual disease represents a major obstacle to the successful treatment of breast cancer, however little is known about the biology of residual tumor cells in vivo. To identify genes differentially expressed in vivo in residual tumor cells compared to primary tumor cells or recurrent tumor cells, we used flow cytometry to isolate GFP-labeled tumor cells from primary, residual, or recurrent tumors grown orthotopically in nu/nu mice. WTA was used to amplify RNA from all tumor cells.

2020-07-24 | GSE60610 | GEO

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Residual tumor cells which remain dormant after MYC inactivation in a primary MYC-HCC derived cell line.

2024-08-06 | GSE242745 | GEO

In vivo isolated HER2/neu-Prim1 Primary, Residual, and Recurrent Tumor Cells, and Recurrent Tumor Stromal Cells

2020-07-24 | GSE60609 | GEO

Risk assessment of parabens in a transcriptomics-based in vitro system

Project description:Risk assessment of parabens in a transcriptomics-based in vitro system

| PRJNA975950 | ENA

Assessment of myogenic maturation for human iPSC-derived iPAX7 myogenic progenitors in vitro and in vivo

Project description:Assessment of myogenic maturation for human iPSC-derived iPAX7 myogenic progenitors in vitro and in vivo

| PRJNA1023472 | ENA